Shares of uniQure N.V. (QURE) surged 74% on Wednesday morning after the company announced a major regulatory milestone for its investigational Huntington's disease treatment, AMT-130.
The stock is currently trading at $46.95, up $19.96 or 73.95%, on the Nasdaq. It opened at $43.63 after closing the previous session at $26.99. The stock has traded between $8.73 and $71.50 over the past 52 weeks.
uniQure said the U.S. Food and Drug Administration informed the company during a recent Type B meeting that three-year data from its Phase I/II study could serve as the primary basis for a Biologics License Application seeking accelerated approval of AMT-130. The company now intends to submit the BLA in the third quarter of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.